Breadcrumb Home Studies Studies Search Filter Research Area All Study Status AllClosed to AccrualClosed to Follow UpConcludedEnrollingIn DevelopmentParticipants Off Study and Primary Analysis CompletedPendingWithdrawn Sort Study Number AscStudy Number Desc Submit Search Showing 134 studies. IMPAACT 2007: Phase I Safety and Pharmacokinetic Study of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection DAIDS Number 20734 Research Area Treatment Study Status Concluded IMPAACT 2005: A Phase I/II Open-Label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination with Optimized Multidrug Background Regimen (OBR) in Children with MDR-TB with and without HIV DAIDS Number 20721 Research Area Tuberculosis Study Status Closed to Follow Up IMPAACT 2003B/A5300B: Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx MDR-TB) DAIDS Number 12041 Research Area Tuberculosis Study Status Closed to Accrual IMPAACT 2003/ACTG 5300: PHOENIx Feasibility Study DAIDS Number 11803 Research Area Tuberculosis Study Status Participants Off Study and Primary Analysis Completed IMPAACT 2002: Combined Cognitive Behavioral Therapy and a Medication Management Algorithm for Treatment of Depression among Youth Living with HIV in the United States DAIDS Number 12051 Research Area Brain and Mental Health Study Status Participants Off Study and Primary Analysis Completed IMPAACT 2001: A Phase I/II Trial of the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-infected and HIV-1-uninfected Pregnant and Postpartum Women with Latent Tuberculosis Infection DAIDS Number 12026 Research Area Tuberculosis Study Status Participants Off Study and Primary Analysis Completed IMPAACT 2000: A Phase I Study of the Safety and Immunogenicity of Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV LID delta M2-2 in RSV-Seronegative Infants and Children DAIDS Number 12016 Research Area Complications & Comorbidities Study Status Concluded P1115: Very Early Intensive Treatment of Infants Living with HIV to Achieve HIV Remission: A Phase I/II Proof of Concept Study DAIDS Number 11954 Research Area Cure and Immunotherapy Study Status Enrolling P1114: Safety and Immunogenicity of an RSV Vaccine cps2 DAIDS Number 11948 Research Area Complications & Comorbidities Study Status Concluded P1113: AERAS-404 TB Vaccine in BCG-Primed Infants DAIDS Number 11911 Research Area Tuberculosis Study Status Closed to Follow Up Pagination Previous page Prev Page 1 Page 2 Page 3 Page 4 Current page 5 Page 6 Page 7 Page 8 Page 9 … Page 14 Next page Next
IMPAACT 2007: Phase I Safety and Pharmacokinetic Study of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection DAIDS Number 20734 Research Area Treatment Study Status Concluded
IMPAACT 2005: A Phase I/II Open-Label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination with Optimized Multidrug Background Regimen (OBR) in Children with MDR-TB with and without HIV DAIDS Number 20721 Research Area Tuberculosis Study Status Closed to Follow Up
IMPAACT 2003B/A5300B: Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx MDR-TB) DAIDS Number 12041 Research Area Tuberculosis Study Status Closed to Accrual
IMPAACT 2003/ACTG 5300: PHOENIx Feasibility Study DAIDS Number 11803 Research Area Tuberculosis Study Status Participants Off Study and Primary Analysis Completed
IMPAACT 2002: Combined Cognitive Behavioral Therapy and a Medication Management Algorithm for Treatment of Depression among Youth Living with HIV in the United States DAIDS Number 12051 Research Area Brain and Mental Health Study Status Participants Off Study and Primary Analysis Completed
IMPAACT 2001: A Phase I/II Trial of the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-infected and HIV-1-uninfected Pregnant and Postpartum Women with Latent Tuberculosis Infection DAIDS Number 12026 Research Area Tuberculosis Study Status Participants Off Study and Primary Analysis Completed
IMPAACT 2000: A Phase I Study of the Safety and Immunogenicity of Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV LID delta M2-2 in RSV-Seronegative Infants and Children DAIDS Number 12016 Research Area Complications & Comorbidities Study Status Concluded
P1115: Very Early Intensive Treatment of Infants Living with HIV to Achieve HIV Remission: A Phase I/II Proof of Concept Study DAIDS Number 11954 Research Area Cure and Immunotherapy Study Status Enrolling
P1114: Safety and Immunogenicity of an RSV Vaccine cps2 DAIDS Number 11948 Research Area Complications & Comorbidities Study Status Concluded
P1113: AERAS-404 TB Vaccine in BCG-Primed Infants DAIDS Number 11911 Research Area Tuberculosis Study Status Closed to Follow Up
